Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV) today and set a price target of $6.00. The company’s shares closed last Thursday at $1.57, close to its 52-week low of $1.40.
According to TipRanks.com, Byrnes has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.3% and a 35.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Nabriva is a Moderate Buy with an average price target of $6.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.00 and a one-year low of $1.40. Currently, Nabriva has an average volume of 2.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
